000136966 001__ 136966
000136966 005__ 20240229105109.0
000136966 0247_ $$2doi$$a10.1074/jbc.RA117.000871
000136966 0247_ $$2pmid$$apmid:29934309
000136966 0247_ $$2pmc$$apmc:PMC6102146
000136966 0247_ $$2ISSN$$a0021-9258
000136966 0247_ $$2ISSN$$a1083-351X
000136966 0247_ $$2altmetric$$aaltmetric:46797002
000136966 037__ $$aDKFZ-2018-01395
000136966 041__ $$aeng
000136966 082__ $$a570
000136966 1001_ $$aSananes, Amiram$$b0
000136966 245__ $$aA potent, proteolysis-resistant inhibitor of kallikrein-related peptidase 6 (KLK6) for cancer therapy, developed by combinatorial engineering.
000136966 260__ $$aBethesda, Md.$$bSoc.$$c2018
000136966 3367_ $$2DRIVER$$aarticle
000136966 3367_ $$2DataCite$$aOutput Types/Journal article
000136966 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1536655303_23574
000136966 3367_ $$2BibTeX$$aARTICLE
000136966 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000136966 3367_ $$00$$2EndNote$$aJournal Article
000136966 520__ $$aHuman tissue kallikrein (KLK) proteases are hormone-like signaling molecules with important functions in cancer pathophysiology. KLK-related peptidase 6 (KLK6), specifically, is highly up-regulated in several types of cancer, where its increased activity promotes cancer invasion and metastasis. This characteristic suggests KLK6 as an attractive target for therapeutic interventions. However, inhibitors that specifically target KLK6 have not yet been reported, possibly because KLK6 shares a high sequence homology and structural similarity with other serine proteases and resists inhibition by many polypeptide inhibitors. Here, we present an innovative combinatorial approach to engineering KLK6 inhibitors via flow cytometry-based screening of a yeast-displayed mutant library of the human amyloid precursor protein Kunitz protease inhibitor domain (APPI), an inhibitor of other serine proteases, such as anionic and cationic trypsins. On the basis of this screening, we generated APPIM17L,I18F,S19F,F34V (APPI-4M), an APPI variant with a KLK6 inhibition constant (Ki ) of 160 pm and a turnover time of 10 days. To the best of our knowledge, APPI-4M is the most potent KLK6 inhibitor reported to date, displaying 146-fold improved affinity and 13-fold improved proteolytic stability compared with WT APPI (APPIWT). We further demonstrate that APPI-4M acts as a functional inhibitor in a cell-based model of KLK6-dependent breast cancer invasion. Finally, the crystal structures of the APPIWT/KLK6 and APPI-4M/KLK6 complexes revealed the structural and mechanistic bases for the improved KLK6 binding and proteolytic resistance of APPI-4M. We anticipate that APPI-4M will have substantial translational potential as both imaging agent and therapeutic.
000136966 536__ $$0G:(DE-HGF)POF3-317$$a317 - Translational cancer research (POF3-317)$$cPOF3-317$$fPOF III$$x0
000136966 588__ $$aDataset connected to CrossRef, PubMed,
000136966 7001_ $$aCohen, Itay$$b1
000136966 7001_ $$aShahar, Anat$$b2
000136966 7001_ $$aHockla, Alexandra$$b3
000136966 7001_ $$0P:(DE-He78)259bdc4ae1354441ccc5a5b8b01f7ccb$$aDe Vita, Elena$$b4$$udkfz
000136966 7001_ $$0P:(DE-He78)f0af962ddbc82430e947390b2f3f6e49$$aMiller, Aubry$$b5$$udkfz
000136966 7001_ $$00000-0003-3121-109X$$aRadisky, Evette S$$b6
000136966 7001_ $$aPapo, Niv$$b7
000136966 773__ $$0PERI:(DE-600)1474604-9$$a10.1074/jbc.RA117.000871$$gVol. 293, no. 33, p. 12663 - 12680$$n33$$p12663 - 12680$$tThe journal of biological chemistry$$v293$$x1083-351X$$y2018
000136966 909CO $$ooai:inrepo02.dkfz.de:136966$$pVDB
000136966 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)259bdc4ae1354441ccc5a5b8b01f7ccb$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000136966 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f0af962ddbc82430e947390b2f3f6e49$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000136966 9131_ $$0G:(DE-HGF)POF3-317$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vTranslational cancer research$$x0
000136966 9141_ $$y2018
000136966 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000136966 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000136966 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000136966 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ BIOL CHEM : 2015
000136966 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000136966 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000136966 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000136966 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000136966 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000136966 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000136966 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000136966 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000136966 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000136966 9201_ $$0I:(DE-He78)G404-20160331$$kG404$$lWirkstoffforschung$$x0
000136966 980__ $$ajournal
000136966 980__ $$aVDB
000136966 980__ $$aI:(DE-He78)G404-20160331
000136966 980__ $$aUNRESTRICTED